CJC-1295, also known as CJC-1295 DAC, is a synthetic analogue of growth hormone-releasing hormone (GHRH) growth hormone-releasing factor (GRF), which was developed by ConjuChem. It is a modified form of GRF (1-29), with an improved half-life. CJC-1295 markedly increases plasma growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels in both animals and humans. Clinical studies have shown that the administration of CJC-1295 may increase body weight, increase total pituitary RNA and growth hormone. The increase in total pituitary RNA and growth hormone suggests that more growth hormone releasing cells were created.
Purity, Formulation & Physical Appearance
GHPeptides™ CJC-1295 DAC has a peptide purity level that exceeds 99.0% as determined by HPLC. This peptide was synthesized with no additives and is supplied as a white lyophilized (freeze-dried) powder.
Solubility & Storage
It is recommended to reconstitute the lyophilized CJC-1295 DAC in sterile water, which can then be further diluted in other aqueous solutions. Lyophilized CJC-1295 DAC although stable at room temperature for 3-4 weeks, should be stored desiccated below -18°C. Upon reconstitution, CJC-1295 DAC should be stored at 4°C out of direct light for between 10-14 days and for future use below -18°C. Prevent repeated freeze-thaw cycles.
This product has been synthesized for in-vitro laboratory studies to be performed with cells or biological molecules. This product is not a drug and has not been approved by the FDA to prevent or cure any medical condition or disease. The purchaser is solely liable for risk involved with using this product for any purpose outside of in vitro studies.
MPA-Lys30,D-Ala2,Gln8,Ala15,Leu27-GRF (1-29) amide
- CAS #: 863288-34-0
- Molecular Formula: C165H269N47O46
- Molar Mass: Da (g/mol)
- Amino Acid Sequence:
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) DAC